These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 28642179)

  • 1. Analysis of Outcomes of Multidisciplinary Management of Gliosarcoma: A Single-Center Study, 2000-2013.
    Jain A; Correia J; Schweder P; McMahon A; Merola J; Aspoas R
    World Neurosurg; 2017 Oct; 106():30-36. PubMed ID: 28642179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary gliosarcoma--clinical experience from a regional cancer centre in north India.
    Biswas A; Kumar N; Kumar P; Vasishta RK; Gupta K; Sharma SC; Patel F; Mathuriya SN
    Br J Neurosurg; 2011 Dec; 25(6):723-9. PubMed ID: 21591852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and outcomes for a modern series of primary gliosarcoma patients.
    Han SJ; Yang I; Ahn BJ; Otero JJ; Tihan T; McDermott MW; Berger MS; Prados MD; Parsa AT
    Cancer; 2010 Mar; 116(5):1358-66. PubMed ID: 20052717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A study of clinico-pathological parameters and O⁶-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma.
    Singh G; Mallick S; Sharma V; Joshi N; Purkait S; Jha P; Sharma MC; Suri V; Julka PK; Mahapatra AK; Singh M; Kale SS; Sarkar C
    Neuropathology; 2012 Oct; 32(5):534-42. PubMed ID: 22380407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series.
    Castelli J; Feuvret L; Haoming QC; Biau J; Jouglar E; Berger A; Truc G; Gutierrez FL; Morandi X; Le Reste PJ; Thillays F; Loussouarn D; Nouhaud E; Crehange G; Antoni D; Vauleon E; de Crevoisier R; Noel G
    J Neurooncol; 2016 Aug; 129(1):85-92. PubMed ID: 27169763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
    Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
    Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical, radiological, and immunohistochemical characteristics and outcomes of primary intracranial gliosarcoma: a retrospective single-centre study.
    Zhang Y; Ma JP; Weng JC; Wang L; Wu Z; Li D; Zhang JT
    Neurosurg Rev; 2021 Apr; 44(2):1003-1015. PubMed ID: 32189095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A Patient with Primary Intraventricular Gliosarcoma and Long-term Survival - a Case Report].
    Kalita O; Zlevorová M; Megová M; Vaverka M; Trojanec R; Tučková L
    Klin Onkol; 2016; 29(6):454-459. PubMed ID: 27951723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary gliosarcoma after diagnosis of glioblastoma: clinical experience with 30 consecutive patients.
    Han SJ; Yang I; Otero JJ; Ahn BJ; Tihan T; McDermott MW; Berger MS; Chang SM; Parsa AT
    J Neurosurg; 2010 May; 112(5):990-6. PubMed ID: 19817543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
    Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
    Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliosarcomas: analysis of 11 cases do two subtypes exist?
    Salvati M; Caroli E; Raco A; Giangaspero F; Delfini R; Ferrante L
    J Neurooncol; 2005 Aug; 74(1):59-63. PubMed ID: 16078109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
    Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
    J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas.
    Noël G; Schott R; Froelich S; Gaub MP; Boyer P; Fischer-Lokou D; Dufour P; Kehrli P; Maitrot D
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):749-55. PubMed ID: 21300471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J; Liao Z; Zhang Z; Ajani J; Swisher S; Chang JY; Jeter M; Guerrero T; Stevens CW; Vaporciyan A; Putnam J; Walsh G; Smythe R; Roth J; Yao J; Allen P; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):427-36. PubMed ID: 15380576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical management and survival outcomes of gliosarcomas in the era of multimodality therapy.
    Damodaran O; van Heerden J; Nowak AK; Bynevelt M; McDonald K; Marsh J; Lee G
    J Clin Neurosci; 2014 Mar; 21(3):478-81. PubMed ID: 24332268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.